نتایج جستجو برای: line chemotherapy

تعداد نتایج: 514303  

2015
Adam M. Brufsky

Global guidelines for the management of locally advanced or metastatic hormone receptor-positive (HR-positive), human epidermal growth factor 2-negative (HER2-negative) breast cancer recommend endocrine therapy as first-line treatment for all patients, regardless of age or postmenopausal status. However, current practice patterns in the United States and Europe suggest that these modes of thera...

Journal: :Chinese journal of cancer 2015
Feng Wang Long Bai Tian-Shu Liu Yi-Yi Yu Ming-Ming He Kai-Yan Liu Hui-Yan Luo Dong-Sheng Zhang Yin Jin Feng-Hua Wang Zhi-Qiang Wang De-Shen Wang Miao-Zhen Qiu Chao Ren Yu-Hong Li Rui-Hua Xu

INTRODUCTION Right-sided colon cancer (RSCC) and left-sided colorectal cancer (LSCRC) differ with respect to their biology and genomic patterns. This study aimed to examine whether the primary tumor location is associated with the response to cetuximab in patients with metastatic colorectal cancer (mCRC). METHODS Patients with mCRC treated with cetuximab and standard chemotherapy as first- or...

2018
Haohua Wang Roujun Peng Xiuxing Chen Rui Jia Chunyue Huang Yuanyuan Huang Liangping Xia Guifang Guo

Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological specimens who received cetuximab and chemotherapy from 2005 to 2015 in the present institution wer...

2016
Zhen-Hai Lu Jian-Hong Peng Fu-Long Wang Yun-Fei Yuan Wu Jiang Yu-Hong Li Xiao-Jun Wu Gong Chen Pei-Rong Ding Li-Ren Li Ling-Heng Kong Jun-Zhong Lin Rong-Xin Zhang De-Sen Wan Zhi-Zhong Pan

This study aimed to assess the efficacy and safety of bevacizumab plus preoperative chemotherapy as first-line treatment for liver-only metastatic colorectal cancer in Chinese patients compared with those of preoperative chemotherapy alone.Patients with histologically confirmed liver-only metastatic colorectal cancer were sequentially reviewed, and received either preoperative chemotherapy plus...

2014
Frédéric Fiteni Marine Jary Franck Monnien Thierry Nguyen Eric Beohou Martin Demarchi Erion Dobi Francine Fein Denis Cleau Serge Fratté Virginie Nerich Franck Bonnetain Xavier Pivot Christophe Borg Stefano Kim

BACKGROUND Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combination regimens have shown efficacy in phase II trials and there is no comparative study between differ...

2016
Huiping Li Bin Shao Yin Yan, Guohong Song Xiaoran Liu Jing Wang Xu Liang

OBJECTIVE To observe the efficacy and safety of trastuzumab combined with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing advanced breast cancer. METHODS A total of 90 patients with HER2-overexpressing advanced breast cancer were enrolled in this study. All patients were diagnosed with ductal invasive breast cancer by pathological analysis, and wer...

Journal: :Japanese journal of clinical oncology 2012
Satoshi Kobayashi Makoto Ueno Shinichi Ohkawa Tomoko Andou Ryo Kameda Naoto Yamamoto Soichiro Morinaga

OBJECTIVE Gemcitabine has been widely used, and cisplatin plus gemcitabine is considered as standard first-line chemotherapy for patients with advanced biliary tract cancer. However, no standard therapy was established following the progression to gemcitabine-containing first-line therapy. As S-1 monotherapy as second-line chemotherapy is still not well known in a practical setting this study a...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015
Gregory A Masters David H Johnson Sarah Temin

PURPOSE To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non-small-cell lung cancer (NSCLC). METHODS An Update Committee of the American Society of Clinical Oncology NSCLC Expert Panel based recommendations on a systematic review of randomized controlled trials from January 2007 to February 2014. RESULTS...

Journal: :The oncologist 2012
Joyce A O'Shaughnessy Manfred Kaufmann Friederike Siedentopf Philippe Dalivoust Marc Debled Nicholas J Robert Nadia Harbeck

The goals of treatment for metastatic breast cancer (MBC) are to prolong overall survival (OS) while maximizing quality of life, palliating symptoms, and delaying tumor progression. For many years, anthracyclines and taxanes have been the mainstay of treatment for MBC, but these agents are now commonly administered earlier in the course of the disease. A recent meta-analysis revealed adverse ef...

2017
Pascale Tomasini Solenn Brosseau Julien Mazières Jean-Philippe Merlio Michèle Beau-Faller Jean Mosser Marie Wislez L'Houcine Ouafik Benjamin Besse Isabelle Rouquette Didier Debieuvre Fabienne Escande Virginie Westeel Clarisse Audigier-Valette Pascale Missy Alexandra Langlais Frank Morin Denis Moro-Sibilot Gérard Zalcman Fabrice Barlesi

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are approved for second-line treatment of EGFR wild-type (EGFR-wt) nonsmall cell lung cancer (NSCLC). However, results from randomised trials performed to compare EGFR-TKIs with chemotherapy in this population did not show any survival benefit. In the era of immunotherapy, many drugs are approved for second-line treatment o...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید